NaviFUS Leverages Taiwan’s Advanced Chip Technology to Advance Non-Invasive Brain Disorder Treatments

Image credit: shutterstock

NaviFUS Corp. is transforming the landscape of brain disorder treatments by harnessing Taiwan’s advanced chip technology to develop next-generation ultrasound-based solutions. By integrating information and communication technology (ICT) into high-end medical devices, NaviFUS enhances signal processing capabilities beyond traditional medical technologies, positioning itself as a global leader in focused ultrasound treatments.

Advancing Brain Disease Treatment with Innovative Technology

NaviFUS' proprietary system employs transcranial focused ultrasound with therapeutic guidance tracking to facilitate targeted drug delivery and neuromodulation. This breakthrough technology offers new treatment possibilities for patients with brain cancer and drug-resistant epilepsy, conditions that often lack effective therapeutic options.

Strong Industry Support and Global Collaborations

NaviFUS has garnered strong backing from leading venture capitalists, including Andy T.C. Chiu (Top Taiwan Venture Capital), Stan Shih (Founder of Acer and Chairman of Himalaya Venture Capital), and Max Wu (Spring Foundation of NCTU). The company has also formed strategic alliances with YoungTek Electronics Corp., Genovate Biotechnology Co., Ltd., and the Focused Ultrasound Foundation, led by renowned neurosurgeon Dr. Neal Kassell. These collaborations are instrumental in advancing NaviFUS’ research, accelerating clinical applications, and expanding its impact globally.

Breakthrough Clinical Achievements in Glioblastoma and Epilepsy

NaviFUS has completed a Phase II clinical trial in Taiwan in combination with Avastin for recurrent glioblastoma (rGBM), achieving promising results:

• 66.7% progression-free survival at six months, compared to the historical rate of 42.6%
• Median progression-free survival of 8.9 months, significantly exceeding the historical benchmark of 4.2 months

These compelling safety and efficacy outcomes have paved the way for a pivotal clinical trial under Taiwan’s regulatory authority.

In the field of drug-resistant epilepsy, early clinical data indicate that the NaviFUS system significantly reduces seizure frequency and duration in patients unresponsive to standard medication. Phase II trials are ongoing in Taiwan, with pilot studies initiated in Australia and the United States, reinforcing the company’s commitment to global patient care.

Global Expansion and Strategic Industry Partnerships

In a move to enhance treatment precision and expand its international footprint, NaviFUS has partnered with Brainlab, a global leader in surgical navigation. Brainlab’s extensive network, spanning 6,300 hospitals across 120 countries, is expected to accelerate the adoption of NaviFUS' ultrasound technology in neurosurgical and oncology applications worldwide.

Taiwan’s Leadership in Smart Healthcare Innovation

Taiwan continues to emerge as a leader in biomedical innovation, and NaviFUS is at the forefront of this movement. Chairman Jen Chen reaffirmed the company’s commitment to advancing medical technology, a sentiment echoed by Acer founder Stan Shih during NaviFUS' pre-listing presentation. As Taiwan’s only high-end medical device company integrating cutting-edge chip technology, NaviFUS is paving the way for the future of non-invasive brain treatments.